Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study

被引:0
|
作者
Chen, Ruo-Yang [1 ]
Li, Da -Wei [1 ]
Wang, Jie-Ying [2 ]
Zhuang, Shao-Yong [1 ]
Wu, Hao-Yu [1 ]
Wu, Jia-Jin [1 ]
Qu, Jun-Wen [1 ]
Sun, Nan [1 ]
Zhong, Chen [1 ]
Zhu, Cheng [3 ]
Zhang, Ming [1 ,5 ]
Yu, Yue-Tian [4 ,5 ]
Yuan, Xiao-Dong [1 ,5 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Dept Clin Res Ctr, Sch Med, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Dis Prevent & Control, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Crit Care Med, Shanghai, Peoples R China
[5] 145 Middle Shandong Rd, Shanghai, Peoples R China
关键词
Trimethoprim-sulfamethoxazole; Kidney transplantation; Pneumocystis jirovecii pneumonia; Fungal infection; Prophylaxis;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To evaluate the efficacy and safety of low-dose trimethoprim (TMP)-sulfamethoxazole (SMX) (TMP-SMX) as the primary prophylaxis for Pneumocystis jirovecii pneumonia (PJP) in adult recipients of kidney transplantation.Methods: Three kinds of prescriptions in kidney recipients were documented, including 20 mg TMP/100 mg SMX oral daily, 20 mg TMP/100 mg SMX oral every other day, and nonprophylaxis. The primary outcome was the incidence of PJP in the first 180 days of follow-up after kidney transplantation. The secondary outcomes were changes in renal and liver function.Results: Among the 1469 recipients, 1066 (72.56%) received 20 mg TMP/100 mg SMX daily, 127 (8.65%) received 20 mg TMP/100 mg SMX every other day, and 276 (18.79%) did not have prophylaxis prescrip-tion. The 276 recipients in the nonprophylaxis group had 124.92 person-years of follow-up, during which PJP occurred in 29 patients, for an incidence rate of 23.21 (95% confidence interval 15.76-32.72) per 100 person-years. The TMP-SMX daily group and the TMP-SMX every other day group had 524.89 and 62.07 person-years of follow-up, respectively, with no occurrence of PJP. There was no significant difference among the three groups in changes in renal and liver function ( P > 0.05, respectively). A total of 111 recipients in each group were enrolled in the propensity score matching analysis. It was revealed that the 111 nonprophylaxis recipients had 51.27 person-years of follow-up and 10 PJP cases. Prophylaxis was considered effective because there was a significant difference between the three groups ( P < 0.001).Conclusion: Low-dose TMP-SMX prophylaxis significantly reduces the incidence of PJP within 6 months after kidney transplantation and has a favorable safety profile.& COPY; 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:209 / 215
页数:7
相关论文
共 38 条
  • [1] Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study
    Chen, Ruo-Yang
    Li, Da-Wei
    Wang, Jie-Ying
    Zhuang, Shao-Yong
    Wu, Hao-Yu
    Wu, Jia-Jin
    Qu, Jun-Wen
    Sun, Nan
    Zhong, Chen
    Zhu, Cheng
    Zhang, Ming
    Yu, Yue-Tian
    Yuan, Xiao-Dong
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 125 : 209 - 215
  • [2] Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients
    Zmarlicka, Monika
    Martin, Spencer T.
    Cardwell, Sophia M.
    Nailor, Michael D.
    PROGRESS IN TRANSPLANTATION, 2015, 25 (03) : 210 - 216
  • [3] Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jirovecii Pneumonia in Deceased Donor Kidney Recipients
    Ji, Jianlei
    Wang, Qinghai
    Huang, Tao
    Wang, Ziyu
    He, Pingli
    Guo, Chen
    Xu, Weijia
    Cao, Yanwei
    Dong, Zhen
    Wang, Hongyang
    INFECTION AND DRUG RESISTANCE, 2021, 14 : 4913 - 4920
  • [4] Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation
    G. V. Ramesh Prasad
    Jill Beckley
    Mohit Mathur
    Madhushankar Gunasekaran
    Michelle M. Nash
    Lindita Rapi
    Michael Huang
    Jeffrey S. Zaltzman
    BMC Infectious Diseases, 19
  • [5] Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation
    Prasad, G. V. Ramesh
    Beckley, Jill
    Mathur, Mohit
    Gunasekaran, Madhushankar
    Nash, Michelle M.
    Rapi, Lindita
    Huang, Michael
    Zaltzman, Jeffrey S.
    BMC INFECTIOUS DISEASES, 2019, 19 (1)
  • [6] LIFELONG PROPHYLAXIS WITH TRIMETHOPRIM-SULFAMETHOXAZOLE FOR PREVENTION OF OUTBREAK OF PNEUMOCYSTIS JIROVECII PNEUMONIA IN KIDNEY TRANSPLANT RECIPIENTS
    Goto, Norihiko
    Takahashi-Nakazato, Ai
    Futamura, Kenta
    Okada, Manabu
    Tsujita, Makoto
    Hiramitsu, Takahisa
    Narumi, Shunji
    Oka, Shinichi
    Watarai, Yoshihiko
    TRANSPLANT INTERNATIONAL, 2017, 30 : 309 - 309
  • [7] Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients
    Tu, Guo-wei
    Ju, Min-jie
    Xu, Ming
    Rong, Rui-ming
    He, Yi-zhou
    Xue, Zhang-gang
    Zhu, Tong-yu
    Luo, Zhe
    NEPHROLOGY, 2013, 18 (11) : 736 - 742
  • [8] Preliminary Study on the Combination Effect of Clindamycin and Low Dose Trimethoprim-Sulfamethoxazole on Severe Pneumocystis Pneumonia After Renal Transplantation
    Gu, Zhun-Yong
    Liu, Wen-Jun
    Huang, Dan-Lei
    Liu, Yu-Jing
    He, Hong-Yu
    Yang, Cheng
    Liu, Yi-Mei
    Xu, Ming
    Rong, Rui-Ming
    Zhu, Du-Ming
    Luo, Zhe
    Ju, Min-Jie
    FRONTIERS IN MEDICINE, 2022, 9
  • [9] Low-dose trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis after allogeneic hematopoietic SCT
    Muto, T.
    Takeuchi, M.
    Kawaguchi, T.
    Tanaka, S.
    Tsukamoto, S.
    Sakai, S.
    Takeda, Y.
    Abe, D.
    Ohwada, C.
    Sakaida, E.
    Shimizu, N.
    Yokote, K.
    Iseki, T.
    Nakaseko, C.
    BONE MARROW TRANSPLANTATION, 2011, 46 (12) : 1573 - 1575
  • [10] Low-dose trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia: a systematic review and meta-analysis
    Huang, Hui-Bin
    Zhu, Yi-Bing
    Yu, Da-Xing
    FRONTIERS IN PHARMACOLOGY, 2024, 15